Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
63°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Myriad Genetics, Inc. - Common Stock
(NQ:
MYGN
)
10.07
+0.37 (+3.81%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Myriad Genetics, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade
March 12, 2025
Piper Sandler upgrades Myriad Genetics to Overweight, citing stock stabilization and new leadership. The firm raises its price target to $12.50.
Via
Benzinga
Why Are Myriad Genetics (MYGN) Shares Soaring Today
March 12, 2025
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 10.6% in the morning session after Piper Sandler analysts upgraded the stock's rating from Neutral to Buy. The improved outlook...
Via
StockStory
This HubSpot Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
March 12, 2025
Via
Benzinga
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
March 11, 2025
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with Myriad...
Via
StockStory
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Analyst Expectations For Myriad Genetics's Future
March 03, 2025
Via
Benzinga
Expert Outlook: Myriad Genetics Through The Eyes Of 8 Analysts
February 12, 2025
Via
Benzinga
Demystifying Myriad Genetics: Insights From 6 Analyst Reviews
January 16, 2025
Via
Benzinga
Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4
March 04, 2025
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Sarepta Therapeutics (NASDAQ:SRPT) and its peers.
Via
StockStory
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO
February 25, 2025
UnitedHealthcare will stop covering Myriad Genetics' GeneSight test in 2025, impacting $45 million in revenue. Myriad reaffirms guidance and names a new CEO.
Via
Benzinga
Why Myriad Genetics (MYGN) Shares Are Plunging Today
February 25, 2025
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 16.1% in the morning session after the company reported a tough quarter(Q4 2024), with revenue missing expectations and 2025...
Via
StockStory
Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect
February 25, 2025
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) will be reporting results tomorrow after the bell. Here’s what you need to know.
Via
StockStory
Myriad Genetics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
December 09, 2024
Via
Benzinga
Where Myriad Genetics Stands With Analysts
November 18, 2024
Via
Benzinga
Analyst Expectations For Myriad Genetics's Future
September 19, 2024
Via
Benzinga
What To Expect From United Therapeutics’s (UTHR) Q4 Earnings
February 25, 2025
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow before market open. Here’s what investors should know.
Via
StockStory
Myriad Genetics (NASDAQ:MYGN) Misses Q4 Sales Targets, Stock Drops
February 24, 2025
Genetic testing company Myriad Genetics (NASDAQ:MYGN) fell short of the market’s revenue expectations in Q4 CY2024, but sales rose 7.1% year on year to $210.6 million. The company’s full-year revenue...
Via
StockStory
What To Expect From Myriad Genetics’s (MYGN) Q4 Earnings
February 23, 2025
Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results tomorrow after market hours. Here’s what you need to know.
Via
StockStory
3 Reasons to Sell MYGN and 1 Stock to Buy Instead
February 17, 2025
Myriad Genetics’s stock price has taken a beating over the past six months, shedding 47.8% of its value and falling to $14.75 per share. This might have investors contemplating their next move.
Via
StockStory
Myriad Genetics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
August 13, 2024
Via
Benzinga
Key Takeaways From Myriad Genetics Analyst Ratings
June 27, 2024
Via
Benzinga
Earnings Scheduled For February 24, 2025
February 24, 2025
Via
Benzinga
This AMD Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
December 09, 2024
Via
Benzinga
Crude Oil Moves Higher; Apple Shares Slide After Q4 Results
November 01, 2024
Via
Benzinga
Exposures
Fossil Fuels
12 Health Care Stocks Moving In Friday's Intraday Session
November 01, 2024
Via
Benzinga
Nasdaq Surges Over 200 Points; Amazon Shares Jump After Strong Results
November 01, 2024
Via
Benzinga
G-III Apparel Posts Upbeat Results, Joins NIO, Yext, Shoe Carnival And Other Big Stocks Moving Higher On Thursday
September 05, 2024
Via
Benzinga
Thermo Fisher Scientific Stock Sees RS Rating Jump To 81
August 13, 2024
Thermo Fisher Scientific stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 77 to 81.
Via
Investor's Business Daily
MYGN Stock Earnings: Myriad Genetics Beats EPS, Beats Revenue for Q2 2024
August 06, 2024
MYGN stock results show that Myriad Genetics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Avantor Stock Earns 84 RS Rating
July 30, 2024
Avantor stock had its Relative Strength (RS) Rating upgraded from 78 to 84 Tuesday amid positive Q2 earnings results.
Via
Investor's Business Daily
The 3 Best Gene Editing Stocks to Buy in July 2024
July 08, 2024
Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks.
Via
InvestorPlace
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.